New 24-Strain pneumonia vaccine enters human trials
NCT ID NCT07600983
First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This study tests a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. The trial includes 854 healthy people aged 2 months and older, split into two phases to check safety and immune response. Participants will receive either the new vaccine or an existing one, and researchers will monitor for side effects and antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24)
- What this could lead to
- If successful, this could lead to a vaccine that protects against 24 types of pneumococcal bacteria, potentially preventing serious infections like pneumonia and meningitis.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 854 participants, so the vaccine may not prove safe or effective in larger studies. Side effects are possible, and the immune response may not be strong enough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STREPTOCOCCUS PNEUMONIAE INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ningling County Center for Disease Control and Prevention
NOT_YET_RECRUITINGShangqiu, China
-
Xiangcheng County Center for Disease Control and Prevention
RECRUITINGXuchang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.